ICU Medical (NASDAQ:ICUI) Given New $191.00 Price Target at KeyCorp

ICU Medical (NASDAQ:ICUI) had its price objective reduced by KeyCorp from $209.00 to $191.00 in a research note released on Monday,Benzinga reports. They currently have an overweight rating on the medical instruments supplier’s stock.

Several other research firms have also weighed in on ICUI. Raymond James set a $97.00 price objective on shares of ICU Medical in a research note on Wednesday, March 12th. StockNews.com raised shares of ICU Medical from a “hold” rating to a “buy” rating in a research note on Wednesday, April 16th. Finally, Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a research report on Tuesday, April 8th. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $162.67.

ICU Medical Trading Down 1.4 %

NASDAQ:ICUI opened at $136.72 on Monday. The stock has a market cap of $3.35 billion, a PE ratio of -29.92 and a beta of 0.86. ICU Medical has a fifty-two week low of $93.36 and a fifty-two week high of $196.26. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.29 and a quick ratio of 1.03. The stock’s 50-day moving average is $145.94 and its two-hundred day moving average is $159.18.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Vanguard Group Inc. boosted its holdings in ICU Medical by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 2,682,065 shares of the medical instruments supplier’s stock worth $416,176,000 after purchasing an additional 17,805 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of ICU Medical by 7.4% in the fourth quarter. JPMorgan Chase & Co. now owns 708,382 shares of the medical instruments supplier’s stock worth $109,920,000 after buying an additional 49,108 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of ICU Medical by 18.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 539,981 shares of the medical instruments supplier’s stock worth $83,788,000 after acquiring an additional 82,982 shares in the last quarter. Northern Trust Corp increased its holdings in shares of ICU Medical by 11.1% during the 4th quarter. Northern Trust Corp now owns 402,342 shares of the medical instruments supplier’s stock valued at $62,431,000 after acquiring an additional 40,187 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of ICU Medical by 1.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 304,155 shares of the medical instruments supplier’s stock valued at $47,196,000 after acquiring an additional 3,048 shares in the last quarter. Institutional investors and hedge funds own 96.10% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.